CSSi LifeSciences and BioMARC have announced a strategic partnership to provide 'fully cohesive product development and support' for vaccine and biologic development.
Following an €8M Series A fundraising round by Eternygen GmBh, the German CRO Evotec AG will help get the virtual biotech’s metabolic disease inhibitor programme to preclinical trials.
In an exclusive licensing agreement with Merck & Co Inc (MSD), Cerveau will take on development of the firm’s investigative PET imaging agent up to Phase III trials for Alzheimer’s Disease.
Sharp Edge Labs will use its propriety biosensor platform to identify lead compounds for Sumitomo Dainippon Pharma – technology that the company says will help focus discussions on outcomes rather than cost.
Worldwide Clinical Trials will support the full scope of Renova Therapeutics Phase III trial for its lead gene therapy product candidate, says the CRO.
Aurobindo Pharma Limited has agreed to buy Portugal-based Generis Farmaceutica SA for €135m in a deal that includes a tablet and capsule plant in Amadora.
Drugmakers must include a transaction identification number when buying or selling machinery for tabletting or encapsulating controlled substances, according to a final ruling from the US DEA.
Danish regulators have banned Europharma DK ApS from making or importing medicines and drug intermediates after identifying serious breaches of GMP at its plant in Esbjerg.
Absorption Systems has announced a technology licensing agreement with Pfizer Inc., in which the pharma company will use the preclinical CRO’s cell lines to test potential drug candidates.
IntelGenx Corp has granted Chemo Group an exclusive worldwide license to commercialize several products – moving the company into the novel drug delivery market.
Teewinot’s Irish subsidiary has been granted a fourth patent for a pharmaceutical cannabinoid manufacturing technique which it says saves both time and money.
Recipharm receives approval to buy Kemwell’s Indian operations and PolyPeptides completes the acquisition of Lonza’s peptide business. Welcome to in-Pharmatechnologist’s 2017 M&A round-up.
Cryoport’s network of cold chain logistics will support the delivery of Gradalis Inc’s autologous cell therapy to various cancer trial sites across the US.
Bruker has bolstered its molecular biologics and mass spectrometric offering through the acquisition of contract manufacturing organisation (CMO) InVivo Biotech.
Crown Bioscience will invest $1m into a new subsidiary in Louisiana state to work alongside a new research facility at the New Iberia Research Center (NIRC).
A Wockhardt facility in India put under import alert last year has received a US FDA warning letter citing issues ranging from data discrepancies to inappropriate aseptic clothing.
GE Healthcare hopes to increase the yield of biopharmaceuticals made using its Chinese Hamster Ovary (CHO) expression system through a partnership with synthetic biology firm Synpromics.
The Gates Foundation has invested $140m in Intarcia Therapeutics Inc to develop the biotech’s needle-free delivery pump for use with an HIV prophylactic therapy.
The Charles Stark Draper Laboratory Inc. has inked a three year partnership with Pfizer to create personalised versions of Draper’s Microphysiological Systems (MPS), for cheaper and more effective preclinical testing.
The EMA has started reviewing drugs tested by Micro Therapeutic Research Labs after an inspection by Dutch and Austrian regulators identified potential data integrity problems.
Catalent has partnered with US non-profit PATH for antibody discovery using the CDMO’s GPEx cell line platform, funded by PATH’s Malaria Vaccine Initiative (MVI).
Turnover in the US for clinical monitoring jobs at contract research organizations (CROs) has remained high despite efforts to increase salaries, according to a recent report.
Baxter International has agreed to pay Claris Lifesciences $625m (€598m) for three manufacturing facilities and a portfolio of 11 approved injectable drugs.
NanoTemper Technologies Gmbh has scored custom from the UK CRO Domainex Ltd., which is using its MicroScale Thermophoresis technology for speedier, “higher quality clinical candidates”.
Bangalore’s Strides Shasun Ltd. has acquired Perrigo API India ltd and its active pharmaceutical manufacturing portfolio for generics for INR1bn ($14.7m).
As holidays shoppers wrap up their presents with ribbons and bows, Outsourcing-Pharma.com reviews how contract pharmaceutical packaging companies help ensure successful patient outcomes with iterative design.
Almac Clinical Technologies, part of the Almac Group, has announced a collaboration with Exostar to help mitigate risk associated with intellectual property.
Total spending on medicines is expected to reach $1.5 trillion by 2021, up 33% from 2016 – with historical amounts of new medicines emerging from the pipeline, according to a recent report by QuintilesIMS Institute.
Smithers Avanza is granted renewal of full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), with “no recommendation for improvements.”
bluebird bio Inc has hired apceth Biopharma GmbH to make its candidate ALD cell therapy Lenti-D and its thalassemia treatment LentiGlobin for the European market.
Lonza has agreed to buy US capsule manufacturer Capsugel for $5.5bn (€5.2bn) in cash in an acquisition the Swiss firm says will expand its drug delivery business and enable savings of CHF100m a year by 2019.
